1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048


Delayed Swiss Exchange  -  05/24 12:40:00 pm EDT
331.45 CHF   +2.14%
12:13pGLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
01:01aData at the 2022 ASCO Annual Meeting Highlight Genentech's Continued Commitment to Innovation in Oncology and Personalized Healthcare
01:00aData at the 2022 ASCO Annual Meeting highlight Roche's continued commitment to innovation in oncology and personalised healthcare
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running

11/15/2021 | 01:01am EDT
  • The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy
  • Roche performed particularly well in Operational Eco-Efficiency, Environmental and Social Reporting

Basel, 15 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) has again been recognised as one of the most sustainable companies in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios.

Roche has maintained its leadership through its sustainability strategy, which is fully embedded in the company’s business and culture.

“We are proud of being recognised once again for our consistent and lasting engagement on sustainability,” says Roche CEO Severin Schwan. “This achievement strongly resonates in the context of our 125-year anniversary, and highlights our heritage and our continued commitment to society.”

Sustainability at Roche
For 125 years, sustainability has been an integral part of Roche’s business. Roche follows a holistic approach when managing sustainability: In addition to improving access to products, the company’s strategy also focuses on achieving continuous progress in areas such as social responsibility, environmental protection, supply chain sustainability, people attraction and retention.

Roche makes its biggest contribution to society by improving healthcare provision. It does so by developing the best diagnostic tests and medicines capable of meeting some of the world’s most pressing medical needs.

Roche is aware that this cannot be done alone. The company knows that the key to creating sustainable value and growth lies in partnering with stakeholders and engaging in open, constructive dialogue. By doing so, Roche generates value for society and achieves sustainable economic growth for the company.

Examples of our activities in sustainability areas can be found here:

About the Dow Jones Sustainability Indices (DJSI)
This global ranking is published annually by the S&P Dow Jones Indices and SAM and measures the performance of the world’s sustainability leaders. SAM invites publicly traded companies to participate. Companies are selected for the indices according to a systematic Corporate Sustainability Assessment (CSA) performed by SAM. Only firms that lead their industries based on this assessment are included in the indices. This is determined by a comprehensive assessment of long-term economic, environmental and social criteria that take account of general as well as industry-specific sustainability trends.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the thirteenth consecutive year, Roche has been recognised as one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17
Sileia Urech
Phone: +41 79 935 81 48
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05


  • 15112021_MR_DJSI_EN

© OMX, source GlobeNewswire - EU Press Releases

All news about ROCHE HOLDING AG
12:13pGLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
01:01aData at the 2022 ASCO Annual Meeting Highlight Genentech's Continued Commitment to Inno..
01:00aData at the 2022 ASCO Annual Meeting highlight Roche's continued commitment to innovati..
05/23Roche Secures Exclusive Licensing Deal For KaliVir's Novel Oncolytic Vaccinia Viruses
05/20Biocon Biologics and Viatris Launch Abevmy (bBevacizumab), Their Third Oncology Biosimi..
05/20Cancer coalition aims to boost access to medicines in poorer countries
05/19ROCHE HOLDINGS AG : Credit Suisse reiterates its Neutral rating
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
05/17AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Add Recommendation
05/16TRANSCRIPT : Roche Holding AG - Special Call
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Sales 2022 63 641 M 65 896 M 65 896 M
Net income 2022 14 938 M 15 467 M 15 467 M
Net Debt 2022 10 926 M 11 313 M 11 313 M
P/E ratio 2022 17,2x
Yield 2022 2,99%
Capitalization 270 B 280 B 280 B
EV / Sales 2022 4,41x
EV / Sales 2023 4,24x
Nbr of Employees 100 920
Free-Float 82,4%
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 324,50 CHF
Average target price 396,90 CHF
Spread / Average Target 22,3%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-14.40%273 052
JOHNSON & JOHNSON4.89%472 179
PFIZER, INC.-10.45%296 704
ABBVIE INC.9.33%261 585
NOVO NORDISK A/S2.29%245 087